NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

August 17, 2005 10:00 ET

Second-Hand Smoke Takes its Toll Later in Life

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Aug 17, 2005) -

Nymox (NASDAQ:NYMX) TobacAlert™ Product Detects Second-Hand Smoke Exposure

There is increasing evidence that exposure to second-hand smoke during childhood can lead to lung cancer later in life even for people who never smoked. Smoking has long been identified as the principal cause of lung cancer, the leading cancer killer in both men and women, with an estimated 87% of all lung cancers being attributed to smoking. But, as noted in a recent Health Journal column in the Wall Street Journal (August 16, 2005), the incidence of lung cancer among never-smokers appears to be rising, with second-hand smoke exposure believed to be one of the causes. The recent news that Dana Reeve, the widow of Christopher Reeve and a never-smoker, has lung cancer illustrates this trend. A recent study of 60,182 never-smokers followed over a seven year period found a marked increase in the risk of lung cancer for adults who reported regular exposure to second-hand smoke during childhood (BMJ 2005; 330(7486):277)

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes.

"The serious health risks posed by second-hand smoke exposure to children and adolescents cannot be ignored," said Brian Doyle, Nymox's Manager of Global Sales and Marketing. "People are often unaware of the nature and extent of second-hand smoke exposure, both to themselves and to their family. TobacAlert™ offers a convenient and easy way to get some objective answers."

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com